Immupharma PLC Update on Cancer Compound IPP-204106 'Nucant'

TIDMIMM

Immupharma PLC

16 November 2016

RNS REACH : FOR IMMEDIATE RELEASE 16 NOVEMBER 2016

IMMUPHARMA PLC

Update on Cancer Compound IPP-204106 'Nucant'

Mechanism of Action Published in Prestigious Medical Journal 'Cancer Research'

ImmuPharma plc (LSE:IMM) ("ImmuPharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company, is pleased to announce that Cancer Research, the prestigious medical journal of the American Association for Cancer Research ("AACR"), has published a fundamental scientific paper disclosing the mechanism of action of the Company's cancer compound IPP-204106.

The IPP-204106 programme, which is a potential treatment for various cancers, involves the development of synthetic peptides, Nucants, which target surface nucleolin with very high affinity and selectivity.

The publication was entitled "Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumour vasculature" and was authored by a number of researchers working within ImmuPharma on the Company's Cancer programme.

The key findings of the study for this compound (referred to in the paper as N6L) were:

-- Nucleolin inhibition is a new anti-cancer therapeutic strategy that has been shown to dually normalise tumour vasculature and reduce its volume

-- As a result, it has the potential to improve dramatically the delivery and efficacy of existing chemotherapeutic drugs, and in particular, for difficult-to-treat tumours such as Pancreatic cancer

Dr. Robert Zimmer, MD, PhD, ImmuPharma's President and head of R&D explains: "The publication of the mechanism of action of the Nucants in Cancer Research is a validation of this novel concept in the treatment of cancer we have been developing in partnership with our collaboration partner, CNRS. It relies on the modulating effect of the Nucants on angiogenesis, the mechanism which controls the formation of micro vessels. Generally, the tumour generated micro vessels are of poor quality and offer a poor supply of blood and oxygen to the tumour. As a consequence, it makes the tumour much more resistant to cytotoxic drugs. By modulating the tumour micro vessels Nucants ameliorate the blood flow, allow a better oxygen supply and increase the intra-tumoural cytotoxic drug concentration. About threefold increase of cytotoxic drug concentration and threefold decrease in tumour size have been observed in preclinical studies. The intended treatment scheme is to pre-treat the patient with Nucant and then deliver the standard dose of cytotoxic drug, Gemcitabin for example in pancreatic cancer.

This is the second time that we have been acknowledged by the ACCR. The first in 2011 when our Cancer compound was chosen to be on the cover of the journal disclosing the specific binding to nucleolin and therefore to tumour cells by the Nucants. It is a pleasing validation of years of research by our scientific team and collaborators and gives us further confidence in the long term potential of our Cancer programme, this compound and its unique mechanism of action".

The publication can be seen at http://cancerres.aacrjournals.org/content/early/2016/10/15/0008-5472.CAN-16-0300 and the website of Cancer Research is http://cancerres.aacrjournals.org/

The 2011 publication can be seen at: http://cancerres.aacrjournals.org/content/71/9/3296

The full 'Abstract' is detailed below:

"Pancreatic cancer is a highly aggressive tumour, mostly resistant to the standard treatments. Nucleolin (NCL) is overexpressed in cancers and its inhibition impairs tumour growth. Herein we showed that NCL was overexpressed in human specimens of pancreatic ductal adenocarcinoma (PDAC) and that the overall survival significantly increased in patients with low levels of NCL. The NCL antagonist N6L strongly impaired the growth of primary tumours and liver metastasis in an orthotopic mouse model of PDAC (mPDAC). Similar anti-tumour effect of N6L has been observed in a highly angiogenic mouse model of pancreatic neuroendocrine tumour RIP-Tag2. N6L significantly inhibited both human and mouse pancreatic cell proliferation and invasion. Notably, the analysis of tumour vasculature revealed a strong increase of pericyte coverage and vessel perfusion both in mPDAC and RIP-Tag2 tumours, in parallel to an inhibition of tumour hypoxia. NCL inhibition directly affected endothelial cell (EC) activation and changed a pro-angiogenic signature. Among the vascular activators, NCL inhibition significantly decreased Ang-2 secretion and expression in ECs, in the tumour and in the plasma of mPDAC mice. As a consequence of the observed N6L-induced tumour vessel normalization, pre-treatment with N6L efficiently improved chemotherapeutic drug delivery and increased the anti-tumour properties of gemcitabine in PDAC mice. In conclusion, NCL inhibition is a new anti-pancreatic cancer therapeutic strategy that dually blocks tumour progression and normalizes tumour vasculature improving the delivery and efficacy of chemotherapeutic drugs. Moreover, we unveiled Ang-2 as a potential target and suitable response biomarker for N6L treatment in pancreatic cancer".

-Ends-

 
 For further information please 
  contact:                                        + 44 (0) 20 
   ImmuPharma plc (www.immupharma.org)     7152 4080 
   Tim McCarthy, Chairman 
   Lisa Baderoon, Head of Investor 
    Relations                             + 44 (0) 7721 
    Twitter: @immupharma                   413496 
   Panmure, Gordon & Co., (NOMAD          +44 (0) 20 
    & Broker)                              7886 2500 
   Freddy Crossley, Duncan Monteith, 
    Corporate Finance 
    Charles Leigh-Pemberton, Corporate 
    Broking 
 
    Northland Capital Partners Limited 
    (Joint Broker) 
    Patrick Claridge, David Hignell, 
    Corporate Finance 
    Rob Rees, John Howes, Corporate        [phone] 
    Broking                                          6625 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEAXFSFLNKFFF

(END) Dow Jones Newswires

November 16, 2016 02:01 ET (07:01 GMT)